322 completed, 82 terminated, 54 unknown, 41 recruiting. 292 Phase 2, 105 Phase 1, 80 Phase 4, 75 Phase 3, 39 Not applicable.
Follow Mycophenolate Mofetil: new trials by email Literature Review of Mycophenolate Mofetil trials Research Report on Mycophenolate Mofetil
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers Cyclophosphamide, Busulfan, Fludarabine - Core Binding Factor Alpha Subunits, Hematologic Neoplasms | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 102 | 2026-10-27 | 2026-10-22 |
| Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant Biospecimen Collection, Busulfan, Computed Tomography - Acute Myeloid Leukemia, Graft Versus Host Disease | Phase 1 | Recruiting | City of Hope Medical Center | 15 | 2026-06-12 | 2026-07-01 |
| Testing the Addition of an Anti-Cancer Drug, Mycophenolate Mofetil, to the Usual Treatment (Radiation Therapy and Temozolomide) for Advanced Brain Cancer Intensity-Modulated Radiation Therapy, Hypofractionated Radiation Therapy, Temozolomide (TMZ) - Advanced Glioblastoma | Phase 2 / Phase 3 | Not yet recruiting | Alliance for Clinical Trials in Oncology | 422 | 2026-06-10 | 2026-05-26 |
| Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS Trial Allogeneic Hematopoietic Stem Cell Transplantation, Axatilimab, Biospecimen Collection - Hematopoietic and Lymphatic System Neoplasm | Phase 2 | Withdrawn | Mayo Clinic | 2026-06-01 | 2026-09-03 | |
| Cord Blood Transplantation in Children and Young Adults With Blood Cancer Cord Blood Units, Total Body Irradiation, Cyclophosphamide - Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 71 | 2026-04-28 | 2026-05-14 |
| Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Biospecimen Collection - Acute Myeloid Leukemia | Phase 1 | Recruiting | OHSU Knight Cancer Institute | 40 | 2026-04-21 | 2026-10-05 |
| MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases Treosulfan, Fludarabine, Total Body Irradiation - AML, MDS | Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 132 | 2026-04-10 | 2026-04-16 |
| ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis Cyclophosphamide, Fludarabine, Thiotepa - Acute Myelogenous Leukemia, Acute Lymphatic Leukemia | Phase 2 | Suspended | Leland Metheny | 20 | 2026-04-08 | 2026-09-10 |
| HORUS-Cytomegalovirus Open Proof-of-concept Exploratory Trial 50% reduction in the dose of MPA, Switch from MPA to a mammalian target of rapamycin inhibitor (mTORi), together with an adapted dose of tacrolimus, standard antiviral therapy along with maintenance of their initial immunosuppressive therapy. - CMV Infection | Phase 4 | Not yet recruiting | Oriol Manuel | 100 | 2026-04-01 | 2026-05-06 |
| A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation Frexalimab, Tacrolimus, rabbit anti-thymocyte globulin - Kidney Transplant Rejection | Phase 2 / Phase 3 | Recruiting | Sanofi | 526 | 2026-03-13 | 2026-10-13 |
| A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant Cyclophosphamide, Mycophenolate Mofetil, Ruxolitinib - Hematologic Malignancies | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 40 | 2026-01-20 | 2026-07-07 |
| Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation mCD19-CAR-CD28-CD3-zeta.(anti-CD19 CAR) retroviral vector-transduced allogeneic peripheral blood lymphocytes (PBL), Fludarabine, Cyclophosphamide - Hematologic Malignancies, Hematologic Neoplasms | Phase 1 | Recruiting | National Cancer Institute (NCI) | 155 | 2025-11-14 | 2026-10-16 |
| Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Aplastic Anemia | Phase 2 | Active not recruiting | Fred Hutchinson Cancer Center | 1 | 2025-09-25 | 2026-05-22 |
| A Randomized Study to Compare Post-transplant Cyclophosphamide, Sirolimus, Ruxolitinib and Post-transplant Cyclophosphamide, Sirolimus, Mycophenolate Mofetil to Prevent Graft Versus Host Disease Mycophenolate Mofetil, Ruxolitinib - AML | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 80 | 2025-07-22 | 2026-05-20 |
| Study of the Efficacy of Nintedanib+Tocilizumab in Patients With Systemic Sclerosis and Interstitial Lung Disease Tocilizumab, Nintedanib, Standard therapy - Systemic Sclerosis, Interstitial Lung Disease | Phase 3 | Recruiting | National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland | 86 | 2025-07-01 | 2026-04-08 |
| Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation Drugs Cyclophosphamide, Fludarabine, Thiotepa - Hematologic Malignancies | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 35 | 2025-03-03 | 2026-04-28 |
| Randomized Controlled Trial of Mycophenolate Mofetil Versus Steroid Therapy in Alcoholic Hepatitis Mycophenolate Mofetil, Prednisone - Alcoholic Hepatitis | Not applicable | Not yet recruiting | Institute of Liver and Biliary Sciences, India | 60 | 2025-01-20 | 2025-01-23 |
| Efficacy and Safety of Telitacicept in the Treatment of Systemic Sclerosis Telitacicept, Mycophenolate Mofetil - Diffuse Cutaneous Systemic Sclerosis | Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 38 | 2025-01-06 | 2025-02-11 |
| Cellular Immunotherapy in Recipients of Human Leukocyte Antigen (HLA)-Mismatched, Living Donor Kidney Transplants MDR-102, Immunosuppressive Agents - Kidney Transplant Rejection | Phase 2 / Phase 3 | Withdrawn | Medeor Therapeutics, Inc. | 2024-12-01 | 2024-06-07 | |
| Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease Rovadicitinib, Imatinib, Methotrexate - Graft-versus-host Disease | Phase 3 | Recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 182 | 2024-11-20 | 2025-12-08 |
Showing 20 of 567. Sign in to see all of them.
Leukemia, Myeloid, Acute (122) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (108) · Myelodysplastic Syndromes (102) · Leukemia, Lymphocytic, Chronic, B-Cell (94) · Lymphoma, Non-Hodgkin (85) · Hodgkin Disease (82) · Multiple Myeloma (80) · Leukemia (75) · Lymphoma, Follicular (65) · Lymphoma (63) · Lymphoma, Mantle-Cell (63) · Lymphoma, Large B-Cell, Diffuse (61) · Lymphoma, B-Cell, Marginal Zone (56) · Myeloproliferative Disorders (54) · Congenital Abnormalities (52)
Fred Hutchinson Cancer Center (77) · National Institute of Allergy and Infectious Diseases (NIAID) (28) · Masonic Cancer Center, University of Minnesota (23) · Astellas Pharma Inc (20) · M.D. Anderson Cancer Center (20) · Hoffmann-La Roche (16) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (15) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (11) · Memorial Sloan Kettering Cancer Center (10) · City of Hope Medical Center (9) · National Cancer Institute (NCI) (7) · University of California, San Francisco (6) · University of Cincinnati (6) · Washington University School of Medicine (6) · Bristol-Myers Squibb (5)
United States (377) · China (51) · Canada (42) · Italy (37) · Germany (32) · France (25) · United Kingdom (21) · Spain (19) · Belgium (17) · Russia (16) · South Korea (16) · Australia (14) · Sweden (14) · Czechia (13) · Brazil (12)
Brenda Sandmaier (18) · David Maloney (7) · Claudio G. Brunstein, MD, PhD (5) · Usama Gergis, MD (5) · Christopher G Kanakry, M.D. (4) · George Georges (4) · Rachel B. Salit (4) · Ann Woolfrey (3) · Asad Bashey, MD, PhD (3)
PMID 32499241, PMID 39513526, PMID 21403127, PMID 22430088, PMID 39382091, PMID 18997171, PMID 19179301, PMID 38864363, PMID 12171484, PMID 12176626, PMID 12176628, PMID 12270445, PMID 12944064, PMID 14655180, PMID 15049798, PMID 15233820, PMID 15466923, PMID 15691277, PMID 15692967, PMID 15919463, PMID 16014059, PMID 16273116, PMID 16382014, PMID 16407509, PMID 16415388, PMID 16468960, PMID 16638802, PMID 16687625, PMID 16737942, PMID 16771810, PMID 16790698, PMID 16899504, PMID 16961774, PMID 17469162, PMID 17485423, PMID 17489822, PMID 17717203, PMID 17901414, PMID 17986340, PMID 17989649, PMID 18035553, PMID 18418404, PMID 18424759, PMID 18431244, PMID 18497677, PMID 18554762, PMID 18557726, PMID 18641099, PMID 18698002, PMID 18725917
P30CA015704 (50), P01CA018029 (15), P01CA078902 (12), P01CA015396 (5), P01CA044991 (5), P30CA006973 (5), P30CA033572 (5), U01HL069294 (4), 2009 (3), P30CA036727 (3), 2018 (2), 2025 (2), P01CA148600 (2), P01HL036444 (2), P01HL122173 (2)